What's in Novavax's pipeline?

Novavax has 31 drugs in our index: 3 marketed, 0 filed, 13 in Phase 3, 6 in Phase 2, 9 in Phase 1.

Which companies overlap with Novavax's portfolio?

Top competitors by shared drug class: GlaxoSmithKline, Pfizer, National Vaccine and Serum Institute, China, Henry M. Jackson Foundation for the Advancement of Military Medicine, Medigen Vaccine Biologics Corp..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/novavax.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Novavax — Portfolio Competitive Intelligence Brief

Novavax (NVAX) pipeline: 3 marketed, 0 filed, 13 Phase 3, 6 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

NVAX (NASDAQ) 3 marketed 0 filed 13 Phase 3 6 Phase 2 9 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
protein subunit: Novavax COVID-19 vaccine	protein subunit: Novavax COVID-19 vaccine	marketed	Protein subunit vaccine	SARS-CoV-2 spike protein	Immunology / Infectious Disease
Pfizer mRNA COVID-19 vaccine	Pfizer mRNA COVID-19 vaccine	marketed
Licensed seasonal influenza vaccine	Licensed seasonal influenza vaccine	marketed	Recombinant protein vaccine with adjuvant	Influenza hemagglutinin (HA) protein	Immunology / Infectious Disease
NVX-CoV2373 + NVX-CoV2515	NVX-CoV2373 + NVX-CoV2515	phase 3	Recombinant protein vaccine	SARS-CoV-2 spike protein (original strain and Omicron variant)	Immunology / Infectious Disease
cTIV	cTIV	phase 3	Recombinant influenza vaccine	Influenza hemagglutinin (HA) antigens	Immunology / Infectious Disease
NVX-CoV2515	NVX-CoV2515	phase 3	Recombinant protein subunit vaccine	SARS-CoV-2 spike protein	Immunology / Infectious Disease
NVX-CoV2705 Vaccine	NVX-CoV2705 Vaccine	phase 3	Recombinant protein subunit vaccine	SARS-CoV-2 spike protein	Immunology / Infectious Disease
SARS-CoV-2 rS/Matrix M1-Adjuvant	SARS-CoV-2 rS/Matrix M1-Adjuvant	phase 3	vaccine	SARS-CoV-2 spike protein	Infectious Disease
NanoFlu	NanoFlu	phase 3	Recombinant nanoparticle vaccine	Influenza hemagglutinin (HA)	Immunology / Infectious Disease
NVX-CoV2540	NVX-CoV2540	phase 3	Recombinant protein vaccine	SARS-CoV-2 spike protein (multiple variant epitopes)	Immunology / Infectious Disease
Novavax COVID-19 Vaccine	Novavax COVID-19 Vaccine	phase 3	Protein subunit vaccine	SARS-CoV-2 spike protein	Immunology
RSV-F Vaccine	RSV-F Vaccine	phase 3	Recombinant protein vaccine	RSV fusion (F) protein	Immunology / Infectious Disease

Therapeutic area mix

Immunology / Infectious Disease · 12
Immunology · 2
Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 4 shared drug classes
Pfizer · 3 shared drug classes
National Vaccine and Serum Institute, China · 2 shared drug classes
Henry M. Jackson Foundation for the Advancement of Military Medicine · 2 shared drug classes
Medigen Vaccine Biologics Corp. · 2 shared drug classes
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 2 shared drug classes
ANRS, Emerging Infectious Diseases · 2 shared drug classes
London School of Hygiene and Tropical Medicine · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Novavax:

Cite this brief

Drug Landscape (2026). Novavax — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/novavax. Accessed 2026-05-14.